08:57 EST Intellia up 24% in premarket at $17.34 as FDA lifts hold on nex-z Phase 3 study
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial
- Intellia Therapeutics announces FDA lift of clinical hold on MAGNITUDE-2 trial
- Cathie Wood’s ARK Adds to Intellia Stock (NTLA) — Here’s What Else It Traded This Week
- Cathie Wood’s ARK Investment buys 57K shares of Intellia Therapeutics today
- Cathie Wood Keeps Loading Up on This Biotech Stock — What’s Driving the Buying Spree?